Immunic (Nasdaq: IMUX) to join investor conferences in March, focusing on oral therapies for neurologic and gastrointestinal diseases.
On March 3, 2026, Immunic, Inc. (Nasdaq: IMUX), a leading biotech company specializing in advanced oral treatments for neurological and gastrointestinal conditions, revealed their involvement in investor conferences during March.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments